Jean‐Mathieu Beauregard

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial

Michela Del Prete, François-Alexandre Buteau, Frédéric Arsenault et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2018 · 184 citations

Medicine, Nuclear Medicine, Oncology +17

Quantitative 177 Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system

Jean‐Mathieu Beauregard, Michael S. Hofman, Jucilene Maria Pereira et al. · Cancer Imaging · 2011 · 152 citations · Full text

Medicine, Nuclear Medicine, Radiology +11

The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy

Jean‐Mathieu Beauregard, Michael S. Hofman, Grace Kong et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2011 · 150 citations

Medicine, Nuclear Medicine, Oncology +14

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study

Michela Del Prete, François-Alexandre Buteau, Jean‐Mathieu Beauregard · European Journal of Nuclear Medicine and Molecular Imaging · 2017 · 118 citations

Medicine, Nuclear Medicine, Oncology +16

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial

Karim Fizazi, Ken Herrmann, Bernd J. Krause et al. · The Lancet Oncology · 2023 · 109 citations · Full text

Medicine, Oncology, Pain Management +14